Human Immune Responses to The Yellow Fever Virus Vaccine
This study is currently recruiting participants.
Verified August 2016 by Sri Edupuganti, MD MPH, Emory University
Information provided by (Responsible Party):
Sri Edupuganti, MD MPH, Emory University
First received: May 19, 2008
Last updated: August 16, 2016
Last verified: August 2016
The objective of this study is to study immune memory generated against the yellow fever vaccine (YFV) in participants who recently received the YFV vaccine. Volunteers who are planning to travel to yellow fever endemic areas will be recruited into this study. Volunteers will receive the yellow fever vaccine at the Hope Clinic of Emory University or at their private health care provider's office. Blood tests will be drawn before the vaccination and at upto 8 visits following vaccination. A volunteers's study participation may will last as short as 1 month or as long as one year depending on the immune responses.
We plan to compare the immune responses in younger people (18 to 45 years) to that of older people (55 or above).
Biological: Yellow fever vaccine
||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
||Human Immune Responses to Yellow Fever Vaccination
Primary Outcome Measures:
- 1. Isolation and characterization of yellow fever vaccine (YFV-17D) specific adaptive immune responses: characterize the magnitude and quality of YFV specific T cell responses, antibody secreting cells and memory B cells. [ Time Frame: Upto 12 months after vaccination ]
Secondary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2020 (Final data collection date for primary outcome measure)
There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
Biological: Yellow fever vaccine
YFV will be given as injection
Other Name: YF-VAX
|Ages Eligible for Study:
||18 Years to 70 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Able to understand and give informed consent
- Age 18-45 years or greater than or equal to 55 years
- If possible, participants agree not to take any vaccines within 30 days before or 30 days after yellow fever vaccination
- Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination.
- Travel to or having lived in a country/area which is endemic for yellow fever
- History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
- Any history of allergy to eggs, chicken or gelatin or to any previous vaccine
- A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
- History of HIV infection, Hepatitis B or Hepatitis C infection
- History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months
- History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial
- Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder.
- Recipient of a blood products or immune globulin product within 42 days of the vaccination visit
- Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration
- Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00694655
|The Hope Clinic of the Emory Vaccine Center
|Decatur, Georgia, United States, 30030 |
|Contact: Eileen Oskinski, BS 404-712-1371 firstname.lastname@example.org |
|Contact: Shashi Nagar, MPH 404-712-1407 email@example.com |
|Sub-Investigator: Mark J Mulligan, MD |
|Sub-Investigator: Rafi Ahmed, PhD |
|Sub-Investigator: Rama Akondy, PhD |
||Rafi Ahmed, PhD
||Sri Edupuganti, MD, MPH
||Sri Edupuganti, MD MPH, Associate Professor, Emory University
History of Changes
|Other Study ID Numbers:
YFV/Human Immune Responses ( Other Identifier: Other )
|Study First Received:
||May 19, 2008
||August 16, 2016
Keywords provided by Sri Edupuganti, MD MPH, Emory University:
yellow fever vaccine
CD8 T cell responses
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 21, 2017
Hemorrhagic Fevers, Viral
Body Temperature Changes
Signs and Symptoms
RNA Virus Infections
Physiological Effects of Drugs